Ovarian Cancer

PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use of these drugs have broadened in recent months.

Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.

Kathleen Moore, MD, discusses the potential of mirvetuximab soravtansine in patients with epithelial ovarian cancer.

Douglas Levine, MD, provides his insight on some of the recent data with PARP inhibitors in ovarian cancer, as well as his predictions for the field in the next several years.

Julia A. Elvin, MD, PhD, discusses genomic research in ovarian cancer and how it could potentially impact treatment decisions for patients.

Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses his study of secondary cytoreductive surgery in ovarian cancer.

The FDA granted a priority review in March to a new drug application for maintenance olaparib, and is scheduled to make its final decision on the PARP inhibitor before the end of the year.

Since the approval of LYNPARZA, over 3,000 US women with germline BRCA-mutated advanced ovarian cancer have been treated with this important medicine.

The future of treatment for ovarian cancer may lie in immunotherapy combinations with PARP inhibitors or checkpoint inhibitors.

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the PARP inhibitor landscape for patients with ovarian cancer.